KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
暂无分享,去创建一个
Sabine Tejpar | N. Normanno | F. Ciardiello | S. Tejpar | Fortunato Ciardiello | W. De Roock | Wendy De Roock | Veerle De Vriendt | Nicola Normanno | V. de Vriendt
[1] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.
[2] Hans Clevers,et al. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. , 2002, Cancer research.
[3] A. Ryan,et al. Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells , 2008, Clinical Cancer Research.
[4] Pierre Laurent-Puig,et al. Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers , 2008, International journal of cancer.
[5] C. Sander,et al. V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.
[6] G. Mills,et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. , 2007, Cancer research.
[7] Stuart Thomson,et al. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy , 2008, Clinical & Experimental Metastasis.
[8] A. Lièvre,et al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti‐EGFR antibodies in colorectal cancer , 2010, International journal of cancer.
[9] Y. Yatabe,et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.
[10] Jeffrey D. Goldsmith,et al. Flt-1-Dependent Survival Characterizes the Epithelial-Mesenchymal Transition of Colonic Organoids , 2003, Current Biology.
[11] W. Sellers,et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. , 2009, Cancer research.
[12] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Baselga,et al. Status of PI3K inhibition and biomarker development in cancer therapeutics. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Li Zhao,et al. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms , 2008, Proceedings of the National Academy of Sciences.
[15] J. C. Lee,et al. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. , 2002, European journal of cancer.
[16] L. Mazzucchelli,et al. Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.
[17] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[18] Xiao-qing Tian,et al. Combined Inhibition of MEK and mTOR Signaling Inhibits Initiation and Progression of Colorectal Cancer , 2009, Cancer investigation.
[19] M. Weiser,et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. , 2007, Cancer letters.
[20] A. Casamassimi,et al. Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts , 2000, Oncogene.
[21] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[22] P. Pandolfi,et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.
[23] J. Settleman,et al. Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.
[24] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[25] J. Willson,et al. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells , 2002, Oncogene.
[26] G. Cavet,et al. Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients , 2005, Clinical Cancer Research.
[27] Y. Humblet,et al. Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyondERASthat predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC) , 2010 .
[28] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[29] A. Sweet-Cordero,et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon , 2008, Nature Genetics.
[30] J. Hauser,et al. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. , 2008, Cancer research.
[31] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[32] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[33] J. Desai,et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. , 2010 .
[34] S. Thomson,et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions , 2008, Clinical & Experimental Metastasis.
[35] C. Compton,et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. , 2004, Cancer research.
[36] M. Leppert,et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[37] Shuji Ogino,et al. Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer , 2005, Clinical Cancer Research.
[38] Roderick Turner,et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] R. Nicholson,et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. , 2004, Endocrine-related cancer.
[40] N. Funel,et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] A. Bardelli,et al. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Ralph Weissleder,et al. Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.
[43] F. J. Ramos,et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Francesca Molinari,et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. , 2010, The Journal of clinical investigation.
[45] K. Kinzler,et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. , 2004, The New England journal of medicine.
[46] D. Wheeler,et al. Nuclear EGFR contributes to acquired resistance to cetuximab , 2009, Oncogene.
[47] L. Ellis,et al. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. , 2003, Cancer research.
[48] Francesca Molinari,et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.
[49] Sabine Tejpar,et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] D. Lambrechts,et al. PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.
[51] J. Vandesompele,et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] C. Erlichman. Fluorouracil and leucovorin for metastatic colorectal cancer. , 1990, Journal of chemotherapy.
[53] R. Wolff,et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.
[54] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[55] J. Reid,et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] N. Hay,et al. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. , 2006, Cancer cell.
[57] Shuji Ogino,et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.
[58] M. Tsao,et al. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. , 2003, Molecular cancer research : MCR.
[59] M. Somerfield,et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[61] E. Van Cutsem,et al. Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study , 2008, Clinical Cancer Research.
[62] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[63] S. Ogino,et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. , 2008, Neoplasia.
[64] F. Cavalli,et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.
[65] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[66] Peter Kraft,et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] A. Bardelli,et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.
[68] M. Belvin,et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. , 2009, Cancer research.
[69] Manuel Hidalgo,et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] M. Moroni,et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] G. Baretton,et al. Overexpression of the insulin‐like growth factor I receptor in human colon carcinomas , 2002, Cancer.
[72] Fiona Ginty,et al. The Relative Distribution of Membranous and Cytoplasmic Met Is a Prognostic Indicator in Stage I and II Colon Cancer , 2008, Clinical Cancer Research.
[73] A. Gazdar,et al. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.
[74] Michael J. Fry,et al. Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.
[75] Laura M. Heiser,et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. , 2009, Cancer research.
[76] I. Çelik,et al. Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. , 2010 .